Letter from the Guest Editor: Arsenal Continued

In this issue of Seminars in Nuclear Medicine, therapy of neuroendocrine malignancies is explored via the norepinephrine and somatostatin pathways. Parisi et al1 describe the use of 131I-mIBG with high-dose chemotherapy followed by autologous stem cell transplant in the New Approaches to Neuroblastoma Therapy consortium trial. Lower norepinephrine transporter expression is seen in MYCN amplified high-risk tumors, and methods to augment transporter expression and use of radiosensitizing agents are discussed.
Source: Seminars in Nuclear Medicine - Category: Nuclear Medicine Authors: Source Type: research